Structure	Catalog	Product Name	CAS	E3 Ligase	Target	Inquiry
	BPL-201613	1-((S)-sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)butyl)piperazin-1-yl)pyridin-3-yl)-3-methyl-1H-indole-4-carboxamide	2653338-60-2	CRBN	EZH2	Inquiry
Molecular Weight: 855.01 Molecular Formula: C48H54N8O7 Boiling Point: 1099.8±65.0°C at 760 Torr Density: 1.37±0.1 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201614	1-((S)-sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperazin-1-yl)pyridin-3-yl)-3-methyl-1H-indole-4-carboxamide	2653338-61-3	CRBN	EZH2	Inquiry
Molecular Weight: 869.04 Molecular Formula: C49H56N8O7 Boiling Point: 1102.7±65.0°C at 760 Torr Density: 1.36±0.1 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201615	1-((S)-sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-(4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexyl)piperazin-1-yl)pyridin-3-yl)-3-methyl-1H-indole-4-carboxamide	2653338-62-4	CRBN	EZH2	Inquiry
Molecular Weight: 883.06 Molecular Formula: C50H58N8O7 Boiling Point: 1105.9±65.0°C at 760 Torr Density: 1.34±0.1 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201616	1-((S)-sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)heptyl)piperazin-1-yl)pyridin-3-yl)-3-methyl-1H-indole-4-carboxamide	2653338-63-5	CRBN	EZH2	Inquiry
Molecular Weight: 897.09 Molecular Formula: C51H60N8O7 Boiling Point: 1109.2±65.0°C at 760 Torr Density: 1.33±0.1 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201617	1-((S)-sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-(4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)octyl)piperazin-1-yl)pyridin-3-yl)-3-methyl-1H-indole-4-carboxamide	2653338-64-6	CRBN	EZH2	Inquiry
Molecular Weight: 911.12 Molecular Formula: C52H62N8O7 Boiling Point: 1112.7±65.0°C at 760 Torr Density: 1.32±0.1 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201618	1-((S)-sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-(4-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)nonyl)piperazin-1-yl)pyridin-3-yl)-3-methyl-1H-indole-4-carboxamide	2653338-65-7	CRBN	EZH2	Inquiry
Molecular Weight: 925.14 Molecular Formula: C53H64N8O7 Boiling Point: 1105.3±65.0°C at 760 Torr Density: 1.31±0.1 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201619	1-((S)-sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-(4-(10-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)decyl)piperazin-1-yl)pyridin-3-yl)-3-methyl-1H-indole-4-carboxamide	2653338-66-8	CRBN	EZH2	Inquiry
Molecular Weight: 939.17 Molecular Formula: C54H66N8O7 Boiling Point: 1109.3±65.0°C at 760 Torr Density: 1.30±0.1 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201620	1-((S)-sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-(4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)undecyl)piperazin-1-yl)pyridin-3-yl)-3-methyl-1H-indole-4-carboxamide	2653338-67-9	CRBN	EZH2	Inquiry
Molecular Weight: 953.18 Molecular Formula: C55H68N8O7 Boiling Point: 1113.4±65.0°C at 760 Torr Density: 1.29±0.1 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201621	1-((S)-sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-(4-(12-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)dodecyl)piperazin-1-yl)pyridin-3-yl)-3-methyl-1H-indole-4-carboxamide	2653338-68-0	CRBN	EZH2	Inquiry
Molecular Weight: 967.23 Molecular Formula: C56H70N8O7 Boiling Point: 1117.6±65.0°C at 760 Torr Density: 1.28±0.1 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201622	N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4'-((4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)butyl)piperazin-1-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3-carboxamide	2653338-69-1	CRBN	EZH2	Inquiry
Molecular Weight: 900.09 Molecular Formula: C51H61N7O8 Boiling Point: 1052.8±65.0°C at 760 Torr Density: 1.261±0.06 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201623	N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4'-((4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperazin-1-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3-carboxamide	2641601-66-1	CRBN	EZH2	Inquiry
Molecular Weight: 914.12 Molecular Formula: C52H63N7O8 Boiling Point: 1057.4±65.0°C at 760 Torr Density: 1.251±0.06 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201624	N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4'-((4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexyl)piperazin-1-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3-carboxamide	2653338-70-4	CRBN	EZH2	Inquiry
Molecular Weight: 928.14 Molecular Formula: C53H65N7O8 Boiling Point: 1062.0±65.0°C at 760 Torr Density: 1.243±0.06 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201625	N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4'-((4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)heptyl)piperazin-1-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3-carboxamide	2641601-67-2	CRBN	EZH2	Inquiry
Molecular Weight: 942.17 Molecular Formula: C54H67N7O8 Boiling Point: 1066.8±65.0°C at 760 Torr Density: 1.234±0.06 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201626	N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4'-((4-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)octyl)piperazin-1-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3-carboxamide	2653338-71-5	CRBN	EZH2	Inquiry
Molecular Weight: 956.20 Molecular Formula: C55H69N7O8 Boiling Point: 1071.6±65.0°C at 760 Torr Density: 1.226±0.06 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201627	N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4'-((4-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)nonyl)piperazin-1-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3-carboxamide	2653338-72-6	CRBN	EZH2	Inquiry
Molecular Weight: 970.23 Molecular Formula: C56H71N7O8 Boiling Point: 1066.6±65.0°C at 760 Torr Density: 1.218±0.06 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201628	N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4'-((4-(10-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)decyl)piperazin-1-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3-carboxamide	2653338-73-7	CRBN	EZH2	Inquiry
Molecular Weight: 984.25 Molecular Formula: C57H73N7O8 Boiling Point: 1071.7±65.0°C at 760 Torr Density: 1.211±0.06 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201629	N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4'-((4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)undecyl)piperazin-1-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3-carboxamide	2653338-74-8	CRBN	EZH2	Inquiry
Molecular Weight: 998.28 Molecular Formula: C58H75N7O8 Boiling Point: 1076.9±65.0°C at 760 Torr Density: 1.203±0.06 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201630	N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4'-((4-(12-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)dodecyl)piperazin-1-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3-carboxamide	2653338-75-9	CRBN	EZH2	Inquiry
Molecular Weight: 1012.31 Molecular Formula: C59H77N7O8 Boiling Point: 1082.1±65.0°C at 760 Torr Density: 1.196±0.06 g/cm3 Description: It is an EZH2-based PROTAC used to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2.
	BPL-201631	7-(3,5-Difluoropyridin-2-yl)-N-((S)-13-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)-2-(piperidin-4-yloxy)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-14,14-dimethyl-11-oxo-3,6,9-trioxa-12-azapentadecyl)-2-methyl-10-((methylsulfonyl)methyl)-3-oxo-3,4,6,7-tetrahydro-2H-2,4,7-triazadibenzo[cd,f]azulene-9-carboxamide	2417370-33-1	VHL	BRD4	Inquiry
Molecular Weight: 1201.39 Molecular Formula: C58H70F2N10O12S2 Density: 1.45±0.1 g/cm3 Description: It is a BRD4 degrader with antiproliferative activity in vitro and antitumor efficacy in vivo.
	BPL-201632	7-(3,5-Difluoropyridin-2-yl)-N-(11-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)-2-(piperidin-4-yloxy)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-11-oxoundecyl)-2-methyl-10-((methylsulfonyl)methyl)-3-oxo-3,4,6,7-tetrahydro-2H-2,4,7-triazadibenzo[cd,f]azulene-9-carboxamide		VHL	BRD4	Inquiry
Molecular Weight: 1195.47 Molecular Formula: C61H76F2N10O9S2 Description: It is a BRD4 degrader with antiproliferative activity in vitro and antitumor efficacy in vivo.

PROTAC Library